Acquisitions, License and Research Agreements (Details 3) (USD $) In Millions, unless otherwise specified		6 Months Ended		3 Months Ended		6 Months Ended				0 Months Ended
	Sep. 30, 2011 Intellect Neurosciences Inc.	Jun. 30, 2013 Intellect Neurosciences Inc. Maximum	Jun. 30, 2013 Halozyme Therapeutics	Dec. 31, 2011 Halozyme Therapeutics Combination Halozyme and Cinryze Product	May 31, 2011 Halozyme Therapeutics Combination Halozyme and Cinryze Product	Jun. 30, 2013 Halozyme Therapeutics Combination Halozyme and Cinryze Product Maximum	Jun. 30, 2013 Halozyme Therapeutics Hereditary Angioedema (HAE) Maximum	Jun. 30, 2013 Halozyme Therapeutics Additional Indications item	Jun. 30, 2013 Halozyme Therapeutics Additional Indications Maximum	Dec. 06, 2012 Sanquin Rest of World (ROW)
License and research agreements disclosures
Up-front licensing fee paid	$ 6.5				$ 9.0
Additional license fees payable on the achievement of certain milestones		120					41		30
Additional license fee paid on achievement of development milestone				3
Number of additional milestone indications								3
License maintenance cost annual			1
Percentage of royalty on net sales						10.00%
Payment made related to amended agreement										$ 1.3